Takeda Pharmaceutical's EPS (Weighted Average and Diluted) fell 1077.59% to $767.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $767.0 million, marking a year-over-year decrease of 1077.59%. This contributed to the annual value of $1.6 billion for FY2025, which is 25396605121210.96% up from last year.
Takeda Pharmaceutical's EPS (Weighted Average and Diluted) amounted to $767.0 million in Q4 2025, which was down 1077.59% from $9.9 billion recorded in Q3 2025.
In the past 5 years, Takeda Pharmaceutical's EPS (Weighted Average and Diluted) registered a high of $9.9 billion during Q3 2025, and its lowest value of -$77.9 million during Q1 2022.
For the 5-year period, Takeda Pharmaceutical's EPS (Weighted Average and Diluted) averaged around $2.3 billion, with its median value being $1.4 billion (2023).
As far as peak fluctuations go, Takeda Pharmaceutical's EPS (Weighted Average and Diluted) tumbled by 10944.01% in 2022, and later surged by 1253621.02% in 2025.
Quarter analysis of 5 years shows Takeda Pharmaceutical's EPS (Weighted Average and Diluted) stood at $377.5 million in 2021, then surged by 72.77% to $652.2 million in 2022, then soared by 161.99% to $1.7 billion in 2023, then crashed by 49.69% to $859.6 million in 2024, then decreased by 10.78% to $767.0 million in 2025.
Its last three reported values are $767.0 million in Q4 2025, $9.9 billion for Q3 2025, and $2.7 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value